(Alliance News) - N4 Pharma PLC on Friday said it has filed a new UK patent application around both the ability of its Nuvec delivery system for cancer treatments and vaccines to be used to manufacture viral vectors and to make viral vectors more efficient in applications.
The pharmaceutical company explained that Nuvec has a structure that allows the easy loading of DNA plasmids.
The manufacture of viral vectors typically requires the use of two or more plasmids. Therefore, Nuvec's ability to efficiently load and deliver multiple plasmids could greatly reduce the cost involved in this process, N4 Pharma said.
In recent research conducted by the company, it has been demonstrated that loading Nuvec with the three plasmids typically used to produce lentivirus, resulted in an increase in the amount of the desired viral vector produced.
Looking ahead, N4 Pharma said it is now working with external consultants to identify how best to enter the virus manufacture and ex-vivo gene therapy markets.
"Whilst investigating the dispersion of Nuvec to improve its in-vivo consistency, we have been undertaking research on the in-vitro applications of Nuvec as all our data shows good and consistent loading and in-vitro transfection using Nuvec," said Chief Executive Nigel Theobald.
AIM-listed N4 Pharma shares were trading 21% higher in London on Friday at 6.23 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
N4 Pharma Plc (N4P)